PI3K inhibitors in the treatment of lymphoma: present and challenges

VernacularTitle:PI3K抑制剂在淋巴瘤治疗中的现状和挑战
Author: Ying FU ¹ ; Huaqing WANG
Author Information

1. 天津市人民医院肿瘤诊疗中心　南开大学人民医院转化医学研究院　天津市中西医结合肿瘤研究所，天津　300121
Keywords: Phosphatidylinositol 3-kinases; Lymphoma; Drug-related side effects and adverse reactions; Inhibitors
From: Journal of International Oncology 2024;51(10):660-666
CountryChina
Language:Chinese
Abstract: Abnormal activation of phosphoinositide 3-kinase (PI3K) pathway is one of the pathogenesis of malignant lymphoma. PI3K inhibitors are new targets for lymphoma treatment in recent years. At present, a variety of different types of PI3K inhibitors have been developed, some of which have been approved for clinical use, and some are still in clinical trials. PI3K inhibitors have multiple side effects. Improving safety and efficacy is an important direction for the future development of PI3K inhibitors.